Treatment outcomes and incidence of brain metastases in pulmonary large cell neuroendocrine carcinoma

Zhao, Yizhou; Castonguay, Mathieu; Wilke, Derek; Xu, Zhaolin; Plourde, Madelaine; Mulroy, Liam; MacNeil, Mary; Bowes, David

doi:10.1016/j.currproblcancer.2018.05.006

Cited by 21 publications

(28 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By parallel comparison, a higher proportion of isolated brain metastasis was found in LCNEC than in ONSCLC, consistent with previous findings. 16,30 However, isolated brain metastasis was not a risk factor to affecting survival outcome between LCNEC and ONSCLC. Furthermore, we found that LCNEC cases had a markedly higher proportion of isolated liver metastasis than ONSCLC, and a higher proportion of liver metastasis in combination with other organs.…”

Section: Discussionmentioning

confidence: 89%

“…1 However, a study showed that stage I patients who underwent surgery alone had a very low five-year OS rate at approximately 29.5%, suggesting that surgery alone is not sufficient and adjuvant therapy is important for early-stage LCNEC. 16 In adjuvant and palliative settings, NSCLC platinum-based chemotherapy and an SCLC regimen including etoposide are generally recommended. [17][18][19][20] For advanced LCNEC, SCLC-like chemotherapy appears to be the best treatment option, with a good response rate but poor OS (8-16 months in different case series).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population‐based analysis

Qiao

Chen

et al. 2019

Thoracic Cancer

View full text Add to dashboard Cite

Background The study was conducted to compare the clinicopathological characteristics, survival outcomes, and metastatic patterns between pulmonary large cell neuroendocrine carcinoma (LCNEC) and other non‐small cell lung cancer (ONSCLC), and to identify the prognostic factors of LCNEC. Methods Data of patients diagnosed with LCNEC and ONSCLC from 2004 to 2014 were obtained from the Surveillance, Epidemiology, and End Results dataset. Pearson’s chi‐square tests were used to compare differences in clinicopathological characteristics. The Kaplan–Meier method was used for survival analysis. A propensity score was used for matching and a Cox proportional hazards model was used for multivariate and subgroup analyses. Results A total of 2368 LCNEC cases and 231 672 ONSCLC cases were identified. LCNEC incidence increased slightly over time. Except for marital status, LCNEC patients had obviously different biological features to ONSCLC patients. Survival analysis showed that LCNEC had poorer outcomes than ONSCLC. Multivariate analysis revealed that female gender, black race, surgery, radiation, and chemotherapy were protective factors for LCNEC. Matched subgroup analysis further demonstrated that most subgroup factors favored ONSCLC, especially in early stage. Early‐stage LCNEC patients had a higher risk of lung cancer‐specific death than early‐stage ONSCLC patients. Moreover, metastatic patterns were different between LCNEC and ONSCLC. LCNEC patients with isolated liver metastasis or combined invasion to other organs had poorer survival rates. Conclusions LCNEC has totally different clinicopathological characteristics and metastatic patterns to ONSCLC. LCNEC also has poorer survival outcomes, primarily because of isolated liver metastasis or combined invasion to other organs. Most subgroup factors are adverse factors for LCNEC.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population‐based analysis

Qiao

Chen

et al. 2019

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…LCNECs have similar gene expression profiles and some common chromosomal alterations as SCLCs, but are separate entities from SCLCs due to differences in expression of CK7, CK18, E-cadherin, and beta catenin [4,5]. Nonetheless, LCNECs have a high distant metastasis rate of 65% similar to SCLC, including a reported 32% brain metastasis rate [6,7]. Although there is no established therapeutic approach, primary surgery should be considered for all surgical candidates, and based on the poor outcomes with surgery alone, systemic therapy could be considered in the adjuvant setting as was done in this case [2].…”

Section: Discussionmentioning

confidence: 99%

“…In the setting of brain metastases, surgery and radiotherapy are considered acceptable palliative approaches [8]. For advanced LCNEC, platinum-/etoposidebased chemotherapy regimens that are applied for SCLCs appear to offer advantages in survival [7,9].…”

Section: Discussionmentioning

confidence: 99%

Pituitary Metastasis of Pulmonary Large Cell Neuroendocrine Carcinoma: A Case Report

Hu¹,

Sengupta

Bowes

2020

Cureus

Self Cite

View full text Add to dashboard Cite

“…LCNEC, introduced in 1991 by Travis et al, denotes an extremely infrequent disease, accounting for about 3% of the lung cancers [1]. SCLC and LCNEC share similar clinical and histological behavior, expressing analogous altered genes, such as TP53, KRAS, and RB1 [2]. In the same way, LCNEC exhibits biological features mimicking non-small cell lung cancer (NSCLC), which is conflicting at the time of establishing a treatment [3].…”

Section: Introductionmentioning

confidence: 99%

A Fatal Case of Large Cell Neuroendocrine Lung Cancer Metastatic to the Brain: A Case Report

Jesus¹,

Gupta²,

Cisneros³

et al. 2019

Cureus

View full text Add to dashboard Cite

show abstract

Treatment outcomes and incidence of brain metastases in pulmonary large cell neuroendocrine carcinoma

Cited by 21 publications

References 42 publications

Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population‐based analysis

Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population‐based analysis

Pituitary Metastasis of Pulmonary Large Cell Neuroendocrine Carcinoma: A Case Report

A Fatal Case of Large Cell Neuroendocrine Lung Cancer Metastatic to the Brain: A Case Report

Contact Info

Product

Resources

About